PFE Stock Price: Pfizer Inc continues to dip despite record COVID-19 cases in the US
Premium|Take advantage of 60% OFF on your first month.
Grab this special offer, it's 7 months for FREE deal! And access ALL our articles and analysis.
You have reached your limit of 5 free articles for this month.
BLACK FRIDAY SALE! 60% OFF!
Grab this special offer, it's 7 months for FREE deal! And access ALL our articles and analysis.
CLAIM OFFER- NYSE: PFE fell by 0.74% during Wednesday’s trading session.
- Vaccine stocks were mixed despite record cases around the world.
- Double dose of the Pfizer vaccine is shown to be 70% effective against the Omicron variant.
NYSE:PFE continued its recent struggles on Wednesday as the stock fell for the second consecutive session despite record cases of COVID-19 surfacing around the world. Shares of Pfizer fell by 0.74% and closed the trading day at $57.58. The US markets traded mostly flat on Wednesday as the NASDAQ was once again the only major index to close the day in the red. The Dow Jones added 90 basis points while the S&P 500 0.14% as both indices closed the session at fresh new record highs once again.
Stay up to speed with hot stocks' news!
Vaccine stocks also continued to pull back despite the rapid spread of the Omicron and Delta variants across the US. Both Pfizer and its vaccine production partner BioNTech (NASDAQ:BNTX) were trading lower on Wednesday, while other vaccine producers like Moderna (NASDAQ:MRNA) and Johnson & Johnson (NYSE:JNJ) were above water. Moderna appeared to be trading lower once again in the morning, but managed to rally into the closing bell. The gain snapped Moderna’s recent seven-day slide, although shares are still down 30% over the past month.
Pfizer stock forecast
Early research has shown that a double dose of the Pfizer vaccine is up to 70% effective against the Omicron variant. While studies have not shown how effective a third booster shot will be, chances are the efficacy of the shots will rise above 70%. Pfizer is preparing more doses to be shipped worldwide in anticipation of high demand for boosters, as well as its recently approved antiviral pill that is already being delivered to some markets around the world.
Like this article? Help us with some feedback by answering this survey:
- NYSE: PFE fell by 0.74% during Wednesday’s trading session.
- Vaccine stocks were mixed despite record cases around the world.
- Double dose of the Pfizer vaccine is shown to be 70% effective against the Omicron variant.
NYSE:PFE continued its recent struggles on Wednesday as the stock fell for the second consecutive session despite record cases of COVID-19 surfacing around the world. Shares of Pfizer fell by 0.74% and closed the trading day at $57.58. The US markets traded mostly flat on Wednesday as the NASDAQ was once again the only major index to close the day in the red. The Dow Jones added 90 basis points while the S&P 500 0.14% as both indices closed the session at fresh new record highs once again.
Stay up to speed with hot stocks' news!
Vaccine stocks also continued to pull back despite the rapid spread of the Omicron and Delta variants across the US. Both Pfizer and its vaccine production partner BioNTech (NASDAQ:BNTX) were trading lower on Wednesday, while other vaccine producers like Moderna (NASDAQ:MRNA) and Johnson & Johnson (NYSE:JNJ) were above water. Moderna appeared to be trading lower once again in the morning, but managed to rally into the closing bell. The gain snapped Moderna’s recent seven-day slide, although shares are still down 30% over the past month.
Pfizer stock forecast
Early research has shown that a double dose of the Pfizer vaccine is up to 70% effective against the Omicron variant. While studies have not shown how effective a third booster shot will be, chances are the efficacy of the shots will rise above 70%. Pfizer is preparing more doses to be shipped worldwide in anticipation of high demand for boosters, as well as its recently approved antiviral pill that is already being delivered to some markets around the world.
Like this article? Help us with some feedback by answering this survey:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.